Advances in anticancer radiopharmaceuticals.
This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as α particles, β or Auger electrons, to cancer cells via a targeting vector. The discov...
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
2013
|
| _version_ | 1826263177478799360 |
|---|---|
| author | Jackson, MR Falzone, N Vallis, K |
| author_facet | Jackson, MR Falzone, N Vallis, K |
| author_sort | Jackson, MR |
| collection | OXFORD |
| description | This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as α particles, β or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as α particle emitters, has also broadened the indications for targeted radiotherapy. |
| first_indexed | 2024-03-06T19:47:34Z |
| format | Journal article |
| id | oxford-uuid:22d99eb6-1f98-44e9-a51e-7f4f9c9518f5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:47:34Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:22d99eb6-1f98-44e9-a51e-7f4f9c9518f52022-03-26T11:40:56ZAdvances in anticancer radiopharmaceuticals.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:22d99eb6-1f98-44e9-a51e-7f4f9c9518f5EnglishSymplectic Elements at Oxford2013Jackson, MRFalzone, NVallis, KThis review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as α particles, β or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as α particle emitters, has also broadened the indications for targeted radiotherapy. |
| spellingShingle | Jackson, MR Falzone, N Vallis, K Advances in anticancer radiopharmaceuticals. |
| title | Advances in anticancer radiopharmaceuticals. |
| title_full | Advances in anticancer radiopharmaceuticals. |
| title_fullStr | Advances in anticancer radiopharmaceuticals. |
| title_full_unstemmed | Advances in anticancer radiopharmaceuticals. |
| title_short | Advances in anticancer radiopharmaceuticals. |
| title_sort | advances in anticancer radiopharmaceuticals |
| work_keys_str_mv | AT jacksonmr advancesinanticancerradiopharmaceuticals AT falzonen advancesinanticancerradiopharmaceuticals AT vallisk advancesinanticancerradiopharmaceuticals |